The BILAG BR study is providing an important source of data for research into lupus treatments.
Already, researchers have used data from the study to look at:
- The short term effectiveness and safety of rituximab for patients whose lupus doesn’t respond well to other treatments.
- Whether it is possible to predict which patients will respond well to treatment with rituximab, and which factors might contribute towards a patient responding well.
- The percentage of lupus patients who could potentially be eligible for treatment with the licenced biologic drug belimumab.
As the study continues, more data will become available for analysis, making the BILAG BR register even more useful for lupus researchers.
Our team of researchers are busy looking at all the information that has been collected in the study to see what they can find out about the safety of biologic therapies, and also about how well they work for people with SLE.
If you have any ideas about what you would like our researchers to look at please get in touch, we would love to hear from you.
Study updates will be provided in our participant newsletter.